Index S&P 500 P/E 24.71 EPS (ttm) 9.21 Insider Own 2.14% Shs Outstand 51.34M Perf Week -7.66%
Market Cap 11.68B Forward P/E 18.29 EPS next Y 12.44 Insider Trans -2.89% Shs Float 50.25M Perf Month -14.62%
Income 474.62M PEG 2.69 EPS next Q 2.06 Inst Own 101.39% Short Float 3.15% Perf Quarter 10.40%
Sales 4.13B P/S 2.83 EPS this Y 3.35% Inst Trans 3.21% Short Ratio 2.94 Perf Half Y 18.55%
Book/sh 70.06 P/B 3.25 EPS next Y 12.82% ROA 6.01% Short Interest 1.58M Perf Year 10.45%
Cash/sh 5.50 P/C 41.35 EPS next 5Y 9.19% ROE 14.44% 52W Range 161.65 - 275.00 Perf YTD -3.74%
Dividend Est. - P/FCF 31.98 EPS past 5Y 14.84% ROI 7.12% 52W High -17.25% Beta 1.44
Dividend TTM - Quick Ratio 1.16 Sales past 5Y 12.89% Gross Margin 33.56% 52W Low 40.77% ATR (14) 6.98
Dividend Ex-Date - Current Ratio 1.52 EPS Y/Y TTM -3.17% Oper. Margin 15.82% RSI (14) 26.95 Volatility 3.15% 2.49%
Employees 21800 Debt/Eq 0.87 Sales Y/Y TTM 3.86% Profit Margin 11.49% Recom 1.94 Target Price 271.56
Option/Short Yes / Yes LT Debt/Eq 0.85 EPS Q/Q -0.65% Payout 0.00% Rel Volume 1.33 Prev Close 230.09
Sales Surprise 2.24% EPS Surprise 2.42% Sales Q/Q -7.85% Earnings Feb 14 BMO Avg Volume 538.99K Price 227.55
SMA20 -11.20% SMA50 -9.68% SMA200 5.52% Trades
Volume 710,218 Change -1.10%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-15-24 Downgrade Guggenheim
Buy → Neutral
Sep-13-23 Initiated TD Cowen
Market Perform
$212
Jul-10-23 Downgrade Citigroup
Buy → Neutral
$260 → $225
Feb-23-23 Upgrade Guggenheim
Neutral → Buy
$255
Jan-12-23 Downgrade Jefferies
Buy → Hold
Sep-30-22 Upgrade Jefferies
Hold → Buy
$240
Aug-25-22 Initiated Credit Suisse
Outperform
$285
Aug-04-22 Downgrade Morgan Stanley
Overweight → Equal-Weight
$350 → $250
May-24-22 Initiated Guggenheim
Neutral
Apr-25-22 Downgrade Jefferies
Buy → Hold
$370 → $280
Apr-07-22 Initiated Stephens
Overweight
$377
Feb-17-22 Upgrade Citigroup
Neutral → Buy
$400
Feb-17-22 Reiterated UBS
Buy
$465 → $420
Feb-17-22 Reiterated Morgan Stanley
Overweight
$465 → $430
Feb-17-22 Reiterated Deutsche Bank
Buy
$409 → $350
Feb-17-22 Reiterated BofA Securities
Buy
$445 → $400
Aug-05-21 Resumed Credit Suisse
Neutral
$385
Dec-16-20 Downgrade Citigroup
Buy → Neutral
$270 → $250
Sep-10-20 Upgrade Jefferies
Hold → Buy
$254
Jul-01-20 Upgrade BofA Securities
Neutral → Buy
$192
Show Previous Ratings
Apr-18-24 12:09PM
Apr-16-24 11:50AM
08:00AM
Apr-12-24 08:00AM
Apr-11-24 09:10AM
08:00AM
Loading…
08:00AM
Apr-09-24 08:00AM
Apr-04-24 08:00AM
Apr-01-24 08:00AM
Mar-27-24 08:00AM
Mar-26-24 09:39AM
Mar-23-24 09:00AM
(The Wall Street Journal)
Mar-21-24 08:00AM
Mar-15-24 11:30AM
10:30AM
09:46AM
Loading…
Mar-14-24 09:46AM
08:00AM
Mar-12-24 08:00AM
12:11AM
Mar-07-24 12:27PM
Mar-01-24 11:32PM
Feb-29-24 02:00AM
Feb-26-24 08:41AM
Feb-21-24 10:40AM
08:00AM
Feb-20-24 01:15PM
08:08AM
Feb-15-24 01:00PM
10:54AM
12:38AM
08:06PM
Loading…
Feb-14-24 08:06PM
(Morningstar Research) +11.30%
09:30AM
09:30AM
08:09AM
07:19AM
(Associated Press Finance)
07:00AM
Feb-13-24 08:20AM
Feb-09-24 09:15AM
Feb-01-24 10:08AM
Jan-29-24 08:00AM
Jan-27-24 09:00AM
Jan-24-24 04:30PM
Jan-23-24 04:30PM
Jan-18-24 09:10AM
Jan-16-24 08:00AM
(Investor's Business Daily)
08:00AM
Jan-12-24 02:02PM
09:00AM
Jan-08-24 08:00AM
Jan-02-24 09:00AM
(The Wall Street Journal)
Dec-19-23 08:01AM
Dec-18-23 08:00AM
Dec-13-23 08:29AM
Dec-12-23 08:00AM
Dec-08-23 11:30AM
Dec-07-23 01:53PM
Dec-05-23 07:29AM
Dec-02-23 01:05AM
Nov-29-23 07:57AM
Nov-28-23 08:00AM
Nov-27-23 08:30AM
Nov-22-23 03:04AM
Nov-20-23 08:34PM
Nov-17-23 06:45PM
08:40AM
Nov-16-23 12:59PM
08:00AM
Nov-13-23 09:04AM
Nov-10-23 12:11PM
Nov-09-23 05:14PM
08:00AM
01:33AM
(Thomson Reuters StreetEvents)
Nov-08-23 03:20PM
10:59AM
09:30AM
08:54AM
08:26AM
07:06AM
(Associated Press Finance)
07:00AM
Nov-06-23 10:27AM
Nov-01-23 10:01AM
09:13AM
Oct-25-23 08:06PM
(Morningstar Research) -5.97%
Oct-24-23 12:10PM
Oct-23-23 10:10AM
Oct-19-23 08:00AM
Oct-16-23 08:30AM
08:00AM
Oct-11-23 08:00AM
Oct-10-23 09:10AM
Oct-05-23 12:55PM
Oct-02-23 11:35AM
Sep-27-23 12:04PM
Sep-26-23 08:02AM
08:00AM
Sep-25-23 11:40AM
08:00AM
Sep-21-23 11:36AM
Sep-20-23 08:30AM
Sep-18-23 12:03PM
Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The RMS segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The DSA segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Knell Michael Gunnar CSVP&Chief Accounting Officer Mar 08 '24 Sale 267.52 808 216,156 7,024 Mar 11 04:42 PM Knell Michael Gunnar CSVP&Chief Accounting Officer Mar 04 '24 Sale 261.05 2,750 717,890 7,832 Mar 05 04:54 PM Creamer Victoria L EVP & Chief People Officer Feb 29 '24 Sale 253.70 5,000 1,268,500 13,550 Mar 01 05:37 PM Parisotto Shannon M CEVP, Disc & Safety Assessment Feb 29 '24 Sale 253.45 3,786 959,545 4,792 Mar 04 04:09 PM Barbo William D Corporate Executive VP & CCO Feb 22 '24 Sale 248.50 4,050 1,006,425 22,879 Feb 23 04:57 PM Parisotto Shannon M CEVP, Disc & Safety Assessment Feb 15 '24 Option Exercise 144.67 5,882 850,949 8,478 Feb 20 05:32 PM Parisotto Shannon M CEVP, Disc & Safety Assessment Feb 15 '24 Sale 241.20 5,882 1,418,767 2,596 Feb 20 05:32 PM LaPlume Joseph W EVP, Corp Strategy & Develop Feb 15 '24 Sale 238.93 838 200,223 24,620 Feb 20 05:20 PM FOSTER JAMES C Chairman, President and CEO Jan 29 '24 Option Exercise 144.67 17,436 2,522,466 227,827 Jan 31 04:59 PM Girshick Birgit Corporate Executive VP & COO Jan 10 '24 Option Exercise 215.19 5,916 1,273,064 50,365 Jan 11 04:09 PM Creamer Victoria L EVP & Chief People Officer Dec 14 '23 Option Exercise 136.70 5,526 755,388 22,032 Dec 18 04:07 PM Creamer Victoria L EVP & Chief People Officer Dec 14 '23 Sale 225.00 5,526 1,243,350 16,506 Dec 18 04:07 PM LaPlume Joseph W EVP, Corp Strategy & Develop Nov 30 '23 Sale 197.73 1,850 365,800 23,133 Dec 01 04:10 PM Girshick Birgit Corporate Executive VP & COO Nov 20 '23 Buy 187.82 1,322 248,298 44,449 Nov 21 05:07 PM FOSTER JAMES C Chairman, President and CEO Nov 14 '23 Buy 178.05 5,620 1,000,641 202,643 Nov 15 09:23 AM LaPlume Joseph W EVP, Corp Strategy & Develop Nov 09 '23 Option Exercise 144.67 9,128 1,320,548 34,111 Nov 13 04:12 PM LaPlume Joseph W EVP, Corp Strategy & Develop Nov 09 '23 Sale 173.48 9,128 1,583,522 24,983 Nov 13 04:12 PM WALLMAN RICHARD F Director Aug 24 '23 Buy 198.79 1,000 198,786 1,000 Aug 29 04:23 PM Barbo William D Corporate Executive VP & CCO Aug 10 '23 Option Exercise 144.67 5,511 797,276 9,103 Aug 14 04:17 PM Knell Michael Gunnar CSVP&Chief Accounting Officer Aug 10 '23 Option Exercise 144.67 1,471 212,810 11,411 Aug 14 04:15 PM Barbo William D Corporate Executive VP & CCO Aug 10 '23 Sale 217.24 5,763 1,251,954 3,592 Aug 14 04:17 PM Knell Michael Gunnar CSVP&Chief Accounting Officer Aug 10 '23 Sale 216.54 1,471 318,530 9,940 Aug 14 04:15 PM LaPlume Joseph W EVP, Corp Strategy & Develop Aug 10 '23 Sale 216.52 700 151,564 24,983 Aug 14 04:11 PM LaPlume Joseph W EVP, Corp Strategy & Develop May 15 '23 Sale 190.39 345 65,685 24,026 May 16 02:18 PM LaPlume Joseph W EVP, Corp Strategy & Develop May 12 '23 Sale 193.03 959 185,116 24,371 May 15 02:49 PM MASSARO GEORGE Director May 11 '23 Sale 193.43 288 55,708 4,964 May 15 02:42 PM
Index RUT P/E - EPS (ttm) -2.93 Insider Own 7.02% Shs Outstand 98.77M Perf Week -13.97%
Market Cap 115.56M Forward P/E - EPS next Y -0.44 Insider Trans 0.73% Shs Float 91.83M Perf Month -50.21%
Income -284.23M PEG - EPS next Q -0.42 Inst Own 71.23% Short Float 5.65% Perf Quarter 47.21%
Sales 147.75M P/S 0.78 EPS this Y 54.53% Inst Trans 2.89% Short Ratio 1.85 Perf Half Y 79.61%
Book/sh -2.07 P/B - EPS next Y 67.20% ROA -55.00% Short Interest 5.19M Perf Year -94.29%
Cash/sh 2.39 P/C 0.49 EPS next 5Y - ROE -42790.17% 52W Range 0.33 - 20.90 Perf YTD 32.01%
Dividend Est. - P/FCF - EPS past 5Y -23.23% ROI - 52W High -94.40% Beta 0.89
Dividend TTM - Quick Ratio 1.33 Sales past 5Y -2.51% Gross Margin 87.24% 52W Low 251.04% ATR (14) 0.23
Dividend Ex-Date - Current Ratio 1.52 EPS Y/Y TTM 6.75% Oper. Margin -182.20% RSI (14) 30.42 Volatility 9.73% 15.14%
Employees 486 Debt/Eq - Sales Y/Y TTM 4.99% Profit Margin -192.37% Recom 4.00 Target Price 1.50
Option/Short Yes / Yes LT Debt/Eq - EPS Q/Q 18.88% Payout - Rel Volume 0.46 Prev Close 1.27
Sales Surprise -30.24% EPS Surprise -34.12% Sales Q/Q -21.03% Earnings Feb 26 AMC Avg Volume 2.80M Price 1.17
SMA20 -37.90% SMA50 -40.75% SMA200 -10.81% Trades
Volume 1,278,178 Change -7.87%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-08-23 Downgrade BofA Securities
Neutral → Underperform
$4 → $2
Jun-26-23 Downgrade William Blair
Outperform → Mkt Perform
Jun-26-23 Downgrade Stifel
Buy → Hold
Jun-26-23 Downgrade Raymond James
Outperform → Mkt Perform
Jun-26-23 Downgrade BofA Securities
Buy → Neutral
Jun-02-23 Upgrade Stifel
Hold → Buy
$23 → $32
Jan-31-23 Upgrade William Blair
Mkt Perform → Outperform
Jan-26-23 Upgrade Raymond James
Mkt Perform → Outperform
$35
Jan-05-23 Upgrade BofA Securities
Neutral → Buy
$18 → $27
Sep-22-21 Downgrade Goldman
Neutral → Sell
$16 → $11
Aug-20-21 Upgrade Raymond James
Underperform → Mkt Perform
Jul-16-21 Downgrade Stifel
Buy → Hold
$55 → $29
Jul-16-21 Downgrade BofA Securities
Buy → Neutral
$29
Apr-07-21 Downgrade Mizuho
Buy → Neutral
$72 → $29
Apr-07-21 Downgrade H.C. Wainwright
Buy → Neutral
Mar-31-21 Upgrade BofA Securities
Neutral → Buy
$47
Mar-02-21 Downgrade Jefferies
Buy → Hold
$75 → $45
Feb-01-21 Initiated H.C. Wainwright
Buy
$58
Oct-26-20 Initiated Raymond James
Underperform
Jul-10-20 Resumed Stifel
Buy
$71
Show Previous Ratings
Apr-03-24 09:32AM
(FierceBiotech.com) -31.94%
Apr-02-24 05:46PM
Mar-26-24 07:00AM
Mar-20-24 03:45PM
Mar-11-24 07:00AM
08:09AM
Loading…
Feb-29-24 08:09AM
Feb-27-24 09:59AM
(Thomson Reuters StreetEvents) +14.59%
Feb-26-24 05:50PM
(Associated Press Finance)
04:40PM
04:34PM
04:15PM
04:06PM
04:05PM
Feb-20-24 07:00AM
Feb-05-24 07:00AM
07:00AM
Loading…
Jan-25-24 07:00AM
Dec-09-23 05:02PM
Nov-07-23 11:01AM
10:01AM
(Thomson Reuters StreetEvents)
Nov-06-23 05:33PM
05:30PM
04:10PM
(Associated Press Finance)
04:01PM
Oct-23-23 07:00AM
Aug-31-23 10:15AM
Aug-30-23 11:09AM
Aug-29-23 06:00PM
(American City Business Journals)
04:15PM
Aug-16-23 09:35AM
Aug-09-23 09:14AM
10:08AM
Loading…
Aug-08-23 10:08AM
(Thomson Reuters StreetEvents) -18.64%
08:59AM
Aug-07-23 07:30PM
05:40PM
04:26PM
04:01PM
Jul-31-23 09:00AM
(American City Business Journals) +7.29%
Jul-25-23 10:49AM
(American City Business Journals) -5.74%
07:00AM
Jul-24-23 07:00AM
Jul-21-23 07:17AM
Jul-19-23 10:50AM
(American City Business Journals) -7.03%
Jul-14-23 09:55AM
Jul-11-23 09:35AM
Jul-01-23 08:46AM
Jun-27-23 12:45PM
Jun-26-23 04:04PM
(Investor's Business Daily) -83.12%
11:34AM
07:22AM
07:11AM
07:04AM
Jun-08-23 01:03PM
Jun-07-23 04:03PM
(Investor's Business Daily) -8.44%
11:47AM
07:02AM
06:55AM
Jun-06-23 04:01PM
02:06PM
(Investor's Business Daily)
May-18-23 07:30AM
May-09-23 10:22AM
(Thomson Reuters StreetEvents)
May-08-23 05:15PM
04:12PM
04:01PM
04:00PM
May-05-23 01:19PM
07:37AM
07:30AM
May-03-23 03:43AM
May-01-23 07:00AM
Apr-24-23 07:00AM
Apr-03-23 07:00AM
Mar-24-23 10:21AM
Mar-11-23 03:27AM
Feb-28-23 02:43PM
(Thomson Reuters StreetEvents)
Feb-27-23 05:25PM
04:01PM
07:00AM
Feb-23-23 11:33AM
07:46AM
Feb-22-23 10:00AM
Feb-20-23 10:00AM
Feb-17-23 07:00AM
Feb-02-23 07:00AM
Jan-16-23 09:34AM
Nov-28-22 07:00AM
Nov-09-22 05:15AM
Nov-07-22 05:45PM
04:01PM
04:00PM
Nov-01-22 07:00AM
Oct-31-22 10:00AM
Oct-24-22 07:00AM
Oct-15-22 09:59AM
Sep-23-22 07:30AM
Aug-26-22 07:00AM
Aug-09-22 06:30AM
Aug-08-22 05:35PM
04:01PM
Jul-25-22 07:00AM
Jul-01-22 07:00AM
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Wettig Thane CEO Mar 07 '24 Buy 1.91 50,000 95,470 470,178 Mar 11 07:06 PM Henderson Jeffrey William Director Sep 01 '23 Sale 1.03 2,000 2,060 28,866 Sep 06 08:54 PM Henderson Jeffrey William Director Aug 04 '23 Sale 1.91 2,000 3,820 30,866 Aug 08 07:10 PM Henderson Jeffrey William Director Jul 11 '23 Sale 2.69 2,000 5,380 32,866 Jul 13 08:28 PM Conterno Enrique A Chief Executive Officer Jul 07 '23 Sale 2.80 1,880 5,264 374,722 Jul 10 07:36 PM Wettig Thane Chief Commercial Officer Jun 23 '23 Sale 16.53 791 13,075 108,261 Jun 26 04:27 PM Chung Christine SVP, China Operations Jun 14 '23 Sale 16.79 6,250 104,925 236,327 Jun 15 08:17 PM Chung Christine SVP, China Operations Jun 13 '23 Sale 17.60 6,250 110,000 242,577 Jun 15 08:17 PM Blaug Suzanne Director Jun 09 '23 Sale 17.20 8,520 146,571 29,594 Jun 09 07:54 PM EDWARDS JEFFREY L Director Jun 09 '23 Sale 17.19 7,889 135,622 33,977 Jun 09 07:53 PM Brennan Aoife Director Jun 09 '23 Sale 17.19 4,733 81,367 27,947 Jun 09 07:55 PM Cravatt Benjamin Director Jun 09 '23 Sale 17.17 3,944 67,717 28,736 Jun 09 07:56 PM Ho Maykin Director Jun 08 '23 Sale 17.44 8,520 148,591 31,501 Jun 09 07:54 PM Henderson Jeffrey William Director Jun 08 '23 Sale 17.46 7,000 122,185 34,866 Jun 09 07:52 PM Conterno Enrique A Chief Executive Officer Jun 07 '23 Sale 17.04 8,897 151,583 376,602 Jun 09 07:10 PM Schoeneck James A Director Jun 07 '23 Sale 18.03 7,100 127,987 73,722 Jun 09 07:51 PM Chung Christine SVP, China Operations Jun 07 '23 Sale 17.04 3,633 61,894 248,827 Jun 09 07:38 PM Eisner Mark EVP, Chief Medical Officer Jun 07 '23 Sale 17.04 2,042 34,792 162,862 Jun 09 07:12 PM Graham Juan Chief Financial Officer Jun 07 '23 Sale 16.99 1,785 30,320 71,083 Jun 09 07:39 PM Wettig Thane Chief Commercial Officer Jun 07 '23 Sale 17.04 1,758 29,951 111,395 Jun 09 07:39 PM Eisner Mark EVP, Chief Medical Officer Jun 02 '23 Sale 18.83 1,090 20,525 164,904 Jun 05 04:22 PM
Index RUT P/E 10.93 EPS (ttm) 3.13 Insider Own 3.34% Shs Outstand 20.60M Perf Week -18.32%
Market Cap 697.89M Forward P/E 8.09 EPS next Y 4.22 Insider Trans -0.22% Shs Float 19.75M Perf Month -13.65%
Income 64.61M PEG 0.73 EPS next Q 0.47 Inst Own 96.94% Short Float 5.60% Perf Quarter -33.06%
Sales 1.21B P/S 0.57 EPS this Y -70.01% Inst Trans -1.66% Short Ratio 4.02 Perf Half Y -33.20%
Book/sh 30.55 P/B 1.12 EPS next Y 53.14% ROA 7.42% Short Interest 1.11M Perf Year -39.70%
Cash/sh 2.73 P/C 12.52 EPS next 5Y 15.00% ROE 10.89% 52W Range 33.89 - 62.36 Perf YTD -37.69%
Dividend Est. - P/FCF 10.73 EPS past 5Y 30.07% ROI 9.76% 52W High -45.22% Beta 1.41
Dividend TTM - Quick Ratio 0.69 Sales past 5Y 24.07% Gross Margin 23.76% 52W Low 0.80% ATR (14) 1.52
Dividend Ex-Date - Current Ratio 1.82 EPS Y/Y TTM -62.10% Oper. Margin 7.49% RSI (14) 25.46 Volatility 5.03% 3.22%
Employees 3095 Debt/Eq 0.07 Sales Y/Y TTM -9.27% Profit Margin 5.32% Recom 2.00 Target Price 47.67
Option/Short Yes / Yes LT Debt/Eq 0.07 EPS Q/Q -71.81% Payout 0.00% Rel Volume 1.67 Prev Close 33.96
Sales Surprise -3.90% EPS Surprise 20.92% Sales Q/Q -37.69% Earnings May 02 BMO Avg Volume 275.26K Price 34.16
SMA20 -16.34% SMA50 -19.42% SMA200 -29.77% Trades
Volume 451,277 Change 0.59%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-15-24 Downgrade Raymond James
Outperform → Mkt Perform
Jun-16-23 Downgrade B. Riley Securities
Buy → Neutral
$69
Apr-19-23 Initiated KeyBanc Capital Markets
Overweight
$65
Sep-30-22 Initiated DA Davidson
Neutral
$50
Sep-30-21 Initiated Wolfe Research
Outperform
$81
Jan-13-21 Upgrade BMO Capital Markets
Market Perform → Outperform
$56 → $86
Sep-22-20 Upgrade Robert W. Baird
Neutral → Outperform
$64
Aug-28-20 Upgrade B. Riley FBR
Neutral → Buy
$75
Jul-15-20 Initiated Robert W. Baird
Neutral
$55
Jun-08-20 Reiterated B. Riley FBR
Neutral
$42 → $53
Apr-06-20 Downgrade B. Riley FBR
Buy → Neutral
$32 → $21
Apr-02-20 Downgrade BMO Capital Markets
Outperform → Market Perform
$60 → $27
Feb-18-20 Upgrade Raymond James
Mkt Perform → Outperform
$56
Jan-15-20 Initiated Berenberg
Buy
$50
Aug-27-19 Reiterated B. Riley FBR
Buy
$62 → $52
Jul-22-19 Downgrade Raymond James
Strong Buy → Mkt Perform
Sep-17-18 Upgrade B. Riley FBR
Neutral → Buy
$46.50 → $60
Sep-07-18 Reiterated B. Riley FBR
Neutral
$41 → $46.50
Aug-23-18 Upgrade Wells Fargo
Market Perform → Outperform
May-03-18 Downgrade Wells Fargo
Outperform → Market Perform
Show Previous Ratings
Today 04:20AM
Apr-18-24 04:30PM
Apr-16-24 07:05PM
Apr-11-24 05:35PM
04:46AM
07:00AM
Loading…
Feb-27-24 07:00AM
Feb-20-24 03:41PM
(Morningstar Research) -9.12%
07:30AM
Feb-16-24 04:30AM
Feb-01-24 09:42AM
Jan-31-24 07:35AM
Jan-30-24 11:16PM
(Thomson Reuters StreetEvents) -18.56%
06:41PM
02:53PM
11:00AM
10:45AM
Loading…
10:45AM
08:15AM
07:59AM
07:13AM
(Associated Press Finance)
07:00AM
Jan-24-24 09:07AM
Jan-16-24 04:30PM
Jan-04-24 03:42PM
03:38PM
Dec-27-23 04:30AM
Dec-15-23 06:42PM
Nov-29-23 10:54AM
Nov-14-23 06:30AM
Nov-09-23 01:57PM
Nov-08-23 07:30AM
03:50PM
Loading…
Nov-03-23 03:50PM
(Morningstar Research) +5.78%
Oct-31-23 10:19PM
(Thomson Reuters StreetEvents)
12:04PM
09:30AM
08:32AM
08:15AM
07:10AM
(Associated Press Finance)
07:00AM
Oct-25-23 10:02AM
Oct-24-23 10:00AM
Oct-17-23 04:30PM
Sep-18-23 04:05PM
Sep-15-23 12:43PM
Aug-31-23 03:17PM
Aug-30-23 04:12PM
11:32AM
09:31AM
12:22AM
(Thomson Reuters StreetEvents)
Aug-29-23 11:07AM
09:30AM
08:15AM
07:21AM
07:00AM
Aug-24-23 11:57AM
Aug-16-23 06:35PM
Aug-15-23 04:30PM
Aug-08-23 06:57AM
Jul-29-23 11:07AM
Jul-27-23 07:35AM
Jul-21-23 12:23PM
12:07PM
Jul-07-23 10:05PM
Jul-03-23 09:32AM
Jun-09-23 08:42AM
Jun-08-23 04:27PM
Jun-07-23 06:26PM
(Morningstar Research) +5.30%
Jun-05-23 06:01PM
May-30-23 04:30PM
May-26-23 08:17AM
May-12-23 07:04AM
May-08-23 01:52AM
May-03-23 09:46PM
(Thomson Reuters StreetEvents)
08:45AM
07:36AM
07:00AM
Apr-27-23 12:10PM
10:02AM
Apr-26-23 10:02AM
Apr-20-23 04:30PM
07:30AM
Apr-16-23 02:01PM
Mar-22-23 02:05PM
Mar-17-23 06:40PM
Feb-23-23 11:38AM
Feb-12-23 02:50PM
Feb-08-23 02:39PM
01:27PM
05:28AM
Feb-07-23 01:46PM
08:25AM
07:00AM
Feb-02-23 06:49PM
Jan-27-23 06:15PM
Jan-25-23 04:30PM
Jan-24-23 07:11AM
Jan-23-23 07:36PM
Jan-19-23 05:23PM
Dec-29-22 09:07AM
Dec-03-22 09:37AM
Nov-04-22 08:30AM
(Thomson Reuters StreetEvents)
Malibu Boats, Inc. is a holding company, which engages in the design, manufacture, and marketing of recreational powerboats. It offers performance sport boats, sterndrive, and outboard boats under the Malibu, Axis, Pursuit, Maverick, Cobia, Pathfinder, Hewes and Cobalt brands. The firm operates through the following segments: Malibu, Saltwater Fishing, and Cobalt. The Malibu segment is involved in the manufacturing, distribution, marketing and sale of Malibu and Axis performance sports boats. The Saltwater Fishing segment includes manufacturing, distribution, marketing and sale of Pursuit boats and the Maverick Boat Group boats. The Cobalt segment participates in the manufacturing, distribution, marketing and sale of Cobalt boats. The company was founded in 1982 and is headquartered in Loudon, TN.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Hooks Michael K. Executive Chair Feb 22 '24 Buy 42.82 12,500 535,250 12,500 Feb 23 04:22 PM Black David Scott Interim CFO Nov 08 '23 Sale 43.40 631 27,385 3,162 Nov 09 04:17 PM Anderson Ritchie L. Chief Operating Officer Nov 07 '23 Sale 44.14 13,360 589,766 42,311 Nov 09 04:16 PM Springer Jackie D. Jr. Chief Executive Officer Jun 07 '23 Option Exercise 42.13 25,000 1,053,250 145,451 Jun 09 04:05 PM Springer Jackie D. Jr. Chief Executive Officer Jun 07 '23 Sale 60.06 25,000 1,501,402 120,451 Jun 09 04:05 PM
Index - P/E 12.67 EPS (ttm) 2.14 Insider Own 2.79% Shs Outstand 93.40M Perf Week -6.14%
Market Cap 2.53B Forward P/E 26.51 EPS next Y 1.02 Insider Trans 0.00% Shs Float 90.93M Perf Month -0.70%
Income 200.00M PEG 0.43 EPS next Q 0.22 Inst Own 66.93% Short Float 5.34% Perf Quarter 1.69%
Sales 1.25B P/S 2.02 EPS this Y -54.88% Inst Trans 0.10% Short Ratio 3.58 Perf Half Y 24.06%
Book/sh 38.21 P/B 0.71 EPS next Y 3.80% ROA -0.67% Short Interest 4.85M Perf Year -55.37%
Cash/sh 3.14 P/C 8.61 EPS next 5Y 29.50% ROE -4.44% 52W Range 20.17 - 64.43 Perf YTD -10.98%
Dividend Est. 3.61 (13.34% ) P/FCF - EPS past 5Y - ROI 2.34% 52W High -57.99% Beta 1.01
Dividend TTM 3.44 (12.72% ) Quick Ratio 1.28 Sales past 5Y 7.45% Gross Margin 13.00% 52W Low 34.21% ATR (14) 1.03
Dividend Ex-Date Feb 05, 2024 Current Ratio 1.33 EPS Y/Y TTM -62.24% Oper. Margin 7.34% RSI (14) 41.29 Volatility 4.51% 3.29%
Employees - Debt/Eq 1.77 Sales Y/Y TTM 3.55% Profit Margin 15.95% Recom 2.39 Target Price 33.12
Option/Short Yes / Yes LT Debt/Eq 1.39 EPS Q/Q 196.37% Payout - Rel Volume 0.93 Prev Close 27.38
Sales Surprise -51.20% EPS Surprise 192.75% Sales Q/Q -12.78% Earnings Apr 23 BMO Avg Volume 1.35M Price 27.07
SMA20 -5.11% SMA50 -4.36% SMA200 -21.61% Trades
Volume 1,259,049 Change -1.13%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-10-24 Initiated Barclays
Equal Weight
$32
Feb-13-24 Initiated Evercore ISI
Outperform
$43
Jan-09-24 Downgrade CIBC
Sector Outperform → Neutral
Nov-09-23 Downgrade Seaport Research Partners
Neutral → Sell
$15.50
Oct-10-23 Downgrade UBS
Buy → Neutral
$74 → $20
Oct-02-23 Downgrade Wells Fargo
Overweight → Equal Weight
$80 → $33
Sep-28-23 Downgrade Oppenheimer
Outperform → Perform
Sep-28-23 Downgrade JP Morgan
Overweight → Neutral
$69 → $40
Aug-29-23 Upgrade Raymond James
Mkt Perform → Outperform
$60
Jun-01-23 Upgrade BofA Securities
Underperform → Neutral
$53 → $60
May-08-23 Upgrade CIBC
Sector Perform → Sector Outperform
Apr-26-23 Downgrade KeyBanc Capital Markets
Overweight → Sector Weight
Apr-21-23 Upgrade JP Morgan
Neutral → Overweight
$81 → $73
Jan-04-23 Upgrade Raymond James
Underperform → Mkt Perform
Jun-17-22 Upgrade RBC Capital Mkts
Sector Perform → Outperform
$86 → $89
Jun-10-22 Initiated CIBC
Neutral
$79
Apr-05-22 Downgrade Raymond James
Mkt Perform → Underperform
Jan-04-22 Downgrade Raymond James
Outperform → Mkt Perform
Sep-21-21 Resumed KeyBanc Capital Markets
Overweight
$89
Aug-26-21 Initiated UBS
Buy
$100
Show Previous Ratings
Apr-16-24 12:00PM
09:55AM
Apr-11-24 08:45AM
Apr-09-24 06:30AM
06:30AM
12:09PM
Loading…
Mar-29-24 12:09PM
Mar-27-24 05:20PM
Mar-14-24 10:56AM
Mar-04-24 06:30AM
Feb-01-24 08:10AM
Jan-31-24 01:30AM
Jan-25-24 11:39AM
08:45AM
07:30AM
07:30AM
07:12AM
Loading…
Jan-23-24 07:12AM
Jan-11-24 06:30AM
06:30AM
Jan-02-24 12:30PM
Dec-28-23 04:05PM
Dec-13-23 11:00AM
06:31AM
Dec-04-23 04:30PM
08:00AM
Nov-28-23 08:19AM
Nov-23-23 11:30AM
Nov-20-23 04:30PM
Nov-12-23 06:24PM
Nov-09-23 11:01AM
Nov-06-23 04:43PM
08:52AM
Loading…
Oct-26-23 08:52AM
(Entrepreneur: Stocks) +7.63%
Oct-24-23 07:30AM
07:30AM
Oct-10-23 04:15PM
04:15PM
Oct-03-23 04:19PM
Oct-02-23 04:28PM
(Yahoo Finance Video) -16.70%
Sep-27-23 04:08PM
06:30AM
Jul-25-23 07:30AM
07:30AM
Jul-11-23 06:30AM
06:30AM
Jun-22-23 07:30AM
May-08-23 07:00AM
06:55AM
Apr-25-23 07:30AM
07:30AM
Apr-11-23 06:30AM
06:30AM
Apr-03-23 08:30AM
Feb-27-23 07:45AM
Jan-25-23 07:30AM
07:30AM
Jan-11-23 06:30AM
Dec-16-22 11:15AM
10:25AM
08:01AM
05:02AM
Dec-15-22 08:00AM
07:48AM
05:15AM
Dec-14-22 10:39AM
Dec-13-22 05:45PM
04:50PM
(Investor's Business Daily)
05:06AM
Dec-11-22 08:49AM
08:00AM
Dec-10-22 10:11AM
08:05AM
Dec-09-22 05:19PM
04:06PM
Dec-08-22 08:31AM
Dec-07-22 05:45PM
04:18PM
08:58AM
07:00AM
Dec-06-22 12:30PM
09:40AM
09:22AM
Dec-04-22 08:45AM
05:06AM
Dec-03-22 07:02AM
Dec-02-22 11:31AM
Dec-01-22 06:06PM
05:45PM
Nov-30-22 12:37PM
09:00AM
Nov-29-22 02:23PM
08:50AM
07:02AM
Nov-25-22 11:40AM
07:00AM
Nov-24-22 09:36AM
05:51AM
Nov-23-22 10:56AM
Nov-22-22 02:49PM
Nov-21-22 08:30AM
06:00AM
Nov-20-22 09:31AM
NextEra Energy Partners LP engages in the acquisition, management, and ownership of contracted clean energy projects with long-term cash flows. It owns interests in wind and solar projects in North America and natural gas infrastructure assets in Texas. The company was founded on March 6, 2014 and is headquartered in Juno Beach, FL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Kind Peter H Director Apr 27 '23 Buy 56.89 1,750 99,558 32,340 Apr 28 04:04 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
